Family Legacy Inc. Has $1,920,000 Position in Amgen Inc. (AMGN)
Family Legacy Inc. continued to hold its position in Amgen Inc. (NASDAQ:AMGN) during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 11,150 shares of the medical research company’s stock at the end of the 2nd quarter. Amgen makes up about 1.9% of Family Legacy Inc.’s investment portfolio, making the stock its 17th largest position. Family Legacy Inc.’s holdings in Amgen were worth $1,920,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other large investors have also recently added to or reduced their stakes in the company. TrimTabs Asset Management LLC increased its position in Amgen by 88.9% in the first quarter. TrimTabs Asset Management LLC now owns 612 shares of the medical research company’s stock worth $100,000 after buying an additional 288 shares during the last quarter. Alpha Omega Wealth Management LLC increased its position in Amgen by 19.0% in the first quarter. Alpha Omega Wealth Management LLC now owns 625 shares of the medical research company’s stock worth $103,000 after buying an additional 100 shares during the last quarter. Jackson Grant Investment Advisers Inc. increased its position in Amgen by 0.6% in the first quarter. Jackson Grant Investment Advisers Inc. now owns 636 shares of the medical research company’s stock worth $104,000 after buying an additional 4 shares during the last quarter. American Beacon Advisors Inc. purchased a new stake in Amgen in the first quarter worth $106,000. Finally, Nelson Roberts Investment Advisors LLC purchased a new stake in Amgen in the first quarter worth $121,000. 78.09% of the stock is owned by institutional investors and hedge funds.
Shares of Amgen Inc. (NASDAQ AMGN) traded down 0.47% during midday trading on Friday, reaching $185.76. The company’s stock had a trading volume of 2,275,630 shares. The company has a market cap of $135.54 billion, a PE ratio of 16.92 and a beta of 1.35. The company’s 50-day moving average price is $175.99 and its 200-day moving average price is $169.31. Amgen Inc. has a 12 month low of $133.64 and a 12 month high of $191.10.
Amgen (NASDAQ:AMGN) last released its quarterly earnings data on Tuesday, July 25th. The medical research company reported $3.27 EPS for the quarter, beating the consensus estimate of $3.11 by $0.16. Amgen had a net margin of 35.46% and a return on equity of 29.85%. The business had revenue of $5.81 billion during the quarter, compared to the consensus estimate of $5.67 billion. During the same quarter in the prior year, the firm earned $2.84 EPS. The business’s revenue was up 2.1% on a year-over-year basis. On average, equities analysts anticipate that Amgen Inc. will post $12.57 EPS for the current fiscal year.
The business also recently disclosed a quarterly dividend, which was paid on Friday, September 8th. Shareholders of record on Thursday, August 17th were issued a dividend of $1.15 per share. This represents a $4.60 annualized dividend and a dividend yield of 2.48%. The ex-dividend date of this dividend was Tuesday, August 15th. Amgen’s dividend payout ratio (DPR) is presently 41.93%.
A number of analysts have issued reports on the company. Royal Bank Of Canada assumed coverage on Amgen in a research report on Thursday, September 14th. They issued a “sector perform” rating and a $192.00 target price for the company. BMO Capital Markets downgraded Amgen from an “outperform” rating to a “market perform” rating in a research report on Wednesday, July 26th. Oppenheimer Holdings, Inc. reissued an “outperform” rating and issued a $203.00 target price (up from $189.00) on shares of Amgen in a research report on Wednesday, July 26th. Deutsche Bank AG reissued a “hold” rating and issued a $174.00 target price (up from $172.00) on shares of Amgen in a research report on Wednesday, July 26th. Finally, Cann reissued a “buy” rating and issued a $203.00 target price (up from $189.00) on shares of Amgen in a research report on Wednesday, July 26th. One equities research analyst has rated the stock with a sell rating, twelve have given a hold rating, eleven have issued a buy rating and two have given a strong buy rating to the company. Amgen presently has a consensus rating of “Buy” and an average price target of $186.14.
ILLEGAL ACTIVITY WARNING: This report was published by Watch List News and is owned by of Watch List News. If you are reading this report on another publication, it was illegally copied and republished in violation of United States and international trademark & copyright legislation. The legal version of this report can be viewed at https://www.watchlistnews.com/family-legacy-inc-has-1920000-position-in-amgen-inc-amgn/1585404.html.
Amgen Company Profile
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN).
Receive News & Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.